Cells are the structural units of all living things. The most fundamental characteristic of cells is their ability to reproduce themselves by dividing. The division of normal and healthy cells occurs in a regulated and systematic fashion. In many parts of the body, the cells continually divide and form new cells to replace old cells that die. For example, when you cut your finger, certain cells divide rapidly until the tissue is healed and the skin is repaired. They will then go back to their normal rate of division. In contrast, cancer cells divide in a haphazard and uncontrolled manner. The result is that they develop into a non-structured mass or tumor. Cancers also have the ability to metastasize; that is to spread through the blood and form tumors at new sites.
Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells, the cells in the body that normally fight infections. There are two main types of white blood cells-lymphoid cells and myeloid cells. ALL affects lymphoid cells. Leukemia cells are abnormal cells that cannot do what normal blood cells do. The abnormal cells are immature white blood cells that cannot help the body fight infections. For this reason, children with ALL often get infections and have fevers. ALL is also called acute lymphocytic leukemia. It is the most common leukemia in children. According to the National Cancer Institute, occurs in about one of every 29,000 children in the United States each year, representing 23 percent of cancer diagnoses among children younger than 15 years of age.
| Company | Product | Phase | |
| Hana Biosciences Inc | Marqibo | II | Acute Lymphoblastic Leukemia |
| NuRx Pharmaceuticals, Inc | NRX5183 | II | Leukemia |
Acute Myelogenous Leukemia
Acute myelogenous leukemia (AML) is a cancer of blood-forming tissues of the bone marrow characterized by the growth of immature white blood cells. White blood cells, which normally help to fight infection, lose their ability to differentiate and then quickly multiply and replace normal cells. Consequently, the patient loses the ability to fight infection and microorganisms. More than 11,900 new cases occur in the United States each year according the National Marrow Donor Program.
| Company | Product | Phase | |
| Kanisa Pharmaceuticals, Inc. | Zosuquidar with gemtuzumab ozogamicin | II | Acute Myelogenous Leukemia |
| CytRx Corporation | TM411 (Third Line Therapy) | II | Acute Myelogenous Leukemia |
| TargeGen, Inc. | TG101348 | II | Acute Myelogenous Leukemia |
| Sunesis Pharmaceuticals Inc | SNS595 with Cytarabine | II | Acute Myelogenous Leukemia |
| Sunesis Pharmaceuticals Inc | SNS595 | II | Acute Myelogenous Leukemia |
| Onyx Pharmaceuticals Inc | Nexavar with Idarubicin and Ara-C | II | Acute Myelogenous Leukemia |
| Onyx Pharmaceuticals Inc w/ Bayer Healthcare Pharmaceuticals | Nexavar | II | Acute Myelogenous Leukemia |
| Kanisa Pharmaceuticals, Inc. | LY335979 with Daunorubicin, Cytarabine | II | Acute Myelogenous Leukemia |
| Isis Pharmaceuticals Inc | LY2181308 | II | Acute Myelogenous Leukemia |
| Geron Corporation | GRNVAC1 | II | Acute Myelogenous Leukemia |
Bladder Cancer
Most bladder cancers are transitional cell carcinomas (cancer that begins in cells that normally make up the inner lining of the bladder). Other types include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). The cells that form squamous cell carcinoma and adenocarcinoma develop in the inner lining of the bladder as a result of chronic irritation and inflammation. The National Cancer Institute estimated 68,810 new cases in 2008.
| Company | Product | Phase | |
| Spectrum Pharmaceuticals Inc | EOquin | III | Bladder Cancer |
| Allergan Inc | EOquin | III | Bladder Cancer |
| Halozyme Therapeutics Inc | Chemophase with Mitomycin | II | Bladder Cancer |
| Genentech, Inc. | Avastin with Gemcitabine and Cisplatin | II | Bladder Cancer |
Brain Tumor
Primary brain tumors are classified as either benign or malignant tumors. If malignant, the tumors generally destroy brain cells and damage those around them. In addition, both benign and malignant brain tumors typically press against the brain, causing the brain to swell and thus increasing the pressure in the skull. The cause of these tumors is unknown and because there are many different types, many different risk factors may play a role. Brain metastases are cancerous tumors which originate from a cancer in another part of the body (e.g., the breast) and subsequently form in the brain. Brain tumors can develop at any age, though gliomas, metastases and meningiomas are more common in adults. The National Institute of Cancer estimated 21, 810 new cases in 2008.
| Company | Product | Phase | |
| Genentech, Inc. | Avastin | M | Brain Tumor |
| BioPro Pharmaceutical Inc | Gliadel Wafer | M | Brain Tumor |
| Neurobiological Technologies Inc | Xerecept | III | Brain Tumor |
| Exelixis Inc | XL184 | III | Brain Tumor |
| Genentech, Inc. | Avastin with Pemetrexed (Second Line Therapy) | II | Brain Metastases |
| Pharmacyclics Inc | Xcytrin with Radiation Therapy and Stereotactic radiosurgery | II | Brain Metastases |
| Amgen Inc | AMG102 | II | Brain Tumor |
| Attenuon LLC | ATN-161 with Carboplatin | II | Brain Tumor |
| Genentech, Inc. | Avastin with Bortezomib | II | Brain Tumor |
| Genentech, Inc. | Avastin with Erlotinib | II | Brain Tumor |
| Genentech, Inc. | Avastin with Etoposide | II | Brain Tumor |
| Genentech, Inc. | Avastin with Radiation, Temozolomide and Irinotecan | II | Brain Tumor |
| Genentech, Inc. | Avastin with Temodar or Etoposide | II | Brain Tumor |
| Genentech, Inc. | Avastin with Temodar, Everolimus and Radiation Therapy (First line therapy) | II | Brain Tumor |
| Genentech, Inc. | Avastin, Temozolomide with Hypofractionated Radiotherapy | II | Brain Tumor |
| BiPar Sciences Inc | BSI-201 with Temodar Plus Radiation Therapy | II | Brain Tumor |
| Peregrine Pharmaceuticals Inc | Cotara | II | Brain Tumor |
| Direct Therapeutics Inc | DTI015 | II | Brain Tumor |
| Genentech, Inc. | Gliadel with Avastin and Irinotecan | II | Brain Tumor |
| Advantagene Inc | GliAtak | II | Brain Tumor |
| Genentech, Inc. | LBH589 with Avastin | II | Brain Tumor |
| Regulon, Inc | LipoVIL12 | II | Brain Tumor |
| Genentech, Inc. | LY317615 with Avastin | II | Brain Tumor |
| HERMES Biosciences | Nanoliposomal irinotecan | II | Brain Tumor |
Breast Cancer
Cancer that forms in tissues of the breast, usually the ducts (tubes that carry milk to the nipple) and lobules (glands that make milk). It occurs in both men and women, although male breast cancer is rare. After lung cancer, breast cancer is the second most fatal cancer to women. Men also are occasionally diagnosed with breast cancer because the tissues are the same as in women. According to the National Cancer Institute, 182,460 (female) and 1,990 (male) new cases were diagnosed in 2008.
| Company | Product | Phase | |
| Abraxis BioScience Inc | Abraxane | M | Breast Cancer |
| Valeant Pharmaceuticals International | Android | M | Breast Cancer |
| Genentech Inc | Avastin with Paclitaxel | M | Breast Cancer |
| Watson Pharmaceuticals Inc | Epirubicin hydrochloride WATSON | M | Breast Cancer |
| Genentech Inc | Herceptin | M | Breast Cancer |
| Genentech, Inc. | Herceptin with anastrozole | M | Breast Cancer |
| Genentech Inc | Herceptin with Chemotherapy | M | Breast Cancer |
| Genentech Inc | Herceptin with Paclitaxel (First Line Therapy) | M | Breast Cancer |
| Genomic Health Inc | Oncotype DX | M | Breast Cancer |
| Amgen Inc | AMG162 | III | Breast Cancer |
| Genentech, Inc. | Avastin | III | Breast Cancer |
| Genentech Inc | Avastin with Chemotherapy (Second Line Therapy) | III | Breast Cancer |
| Genentech Inc | Avastin with Docetaxel (First Line Therapy) | III | Breast Cancer |
| Genentech Inc | Avastin with Herceptin and Docetaxel (First Line Therapy) | III | Breast Cancer |
| Genentech, Inc. | Avastin with hormonal therapy | III | Breast Cancer |
| BiPar Sciences, Inc. | BSI201 with Gemcitabine and Carboplatin | III | Breast Cancer |
| Johnson & Johnson | Doxil (pegylated liposomal doxorubicin hydrochloride) | III | Breast Cancer |
| Genentech, Inc. | Herceptin with Taxol, Fluorouracil, Cytoxan and Epirubicin | III | Breast Cancer |
| Genentech Inc | Omnitarg with Herceptin (First Line Therapy) | III | Breast Cancer |
| Genentech, Inc. | R3502 (Second Line Therapy) | III | Breast Cancer |
| Amgen Inc | Trastuzumab with Neupogen and Vinorelbine | III | Breast Cancer |
| Abraxis BioScience Inc | Abraxane with Avastin | II | Breast Cancer |
| Abraxis BioScience, Inc. | Abraxane with Gemcitabine and Epirubicin | II | Breast Cancer |
| Abraxis BioScience Inc | Abraxane with Trastuzumab and Carboplatin | II | Breast Cancer |
| Genentech, Inc. | ABT869 with Paclitaxel (First Line Therapy) | II | Breast Cancer |
| Amgen Inc | AMG386 | II | Breast Cancer |
| Amgen Inc | AMG479 | II | Breast Cancer |
| Amgen Inc | AMG706 | II | Breast Cancer |
| Attenuon LLC | ATN224 with Letrozole | II | Breast Cancer |
| Genentech, Inc. | Avastin | II | Breast Cancer |
| Genentech, Inc. | Avastin with Abraxane (Second Line Therapy) | II | Breast Cancer |
| Genentech, Inc. | Avastin with Abraxane, Carboplatin, Doxorubicin, Cyclophosphamide and Pegfilgrastim | II | Breast Cancer |
| Abraxis BioScience, Inc. | Avastin with Abraxane, Carboplatin, Doxorubicin, Cyclophosphamide and Pegfilgrastim | II | Breast Cancer |
| Genentech, Inc. | Avastin with Carboplatin | II | Breast Cancer |
| Genentech, Inc. | Avastin with Carboplatin, and Abraxane | II | Breast Cancer |
| Genentech, Inc. | Avastin with Chemotherapy | II | Breast Cancer |
| Genentech Inc | Avastin with Cisplatin | II | Breast Cancer |
| Genentech, Inc. | Avastin with Doxorubicin, Cyclophosphamide, Docetaxel and Capecitabine | II | Breast Cancer |
| Genentech, Inc. | Avastin with Epirubicin, Cyclophosphamide, Docetaxel and Herceptin | II | Breast Cancer |
| Genentech, Inc. | Avastin with Gemzar and Taxol (First Line Therapy) | II | Breast Cancer |
| Genentech, Inc. | Avastin with Herceptin and Taxotere | II | Breast Cancer |
| Genentech Inc | Avastin with Letrozole | II | Breast Cancer |
| Genentech, Inc. | Avastin with Vinorelbine and Trastuzumab | II | Breast Cancer |
| Genentech, Inc. | Avastin with Xeloda and Docetaxel | II | Breast Cancer |
| Genentech, Inc. | Avastin, Docetaxel and Cyclophosphamide with Doxorubicin | II | Breast Cancer |
| Genentech, Inc. | Avastin, Trastuzumab with ABI007, Carboplatin | II | Breast Cancer |
| Abraxis BioScience, Inc. | Avastin, Trastuzumab with ABI007, Carboplatin | II | Breast Cancer |
| Peregrine Pharmaceuticals Inc | Bavituximab with Carboplatin and Paclitaxel | II | Breast Cancer |
| Peregrine Pharmaceuticals Inc | Bavituximab with Chemotherapy | II | Breast Cancer |
| Bionovo Inc | Bezielle | II | Breast Cancer |
| BiPar Sciences Inc | BSI-201 with Irinotecan | II | Breast Cancer |
| Tragara Pharmaceuticals, Inc. | Capoxigem | II | Breast Cancer |
| Cougar Biotechnology, Inc. | CB7630 | II | Breast Cancer |
| Genentech, Inc. | Doxil, Paclitaxel, Cyclophosphamide with Avastin | II | Breast Cancer |
| Genentech, Inc. | Doxorubicin, Cyclophosphamide, Paclitaxel with Avastin | II | Breast Cancer |
| Genentech, Inc. | Femara with Avastin | II | Breast Cancer |
| Genentech, Inc. | Gemcitabine, Carboplatin with or without Herceptin | II | Breast Cancer |
| Genentech, Inc. | Gemzar with Avastin (First Line Therapy) | II | Breast Cancer |
| Geron Corp | GRN163L with Paclitaxel and Bevacizumab | II | Breast Cancer |
| Genentech, Inc. | Herceptin with Cyclophosphamide and Allogeneic GM-CSF-Secreting Breast Tumor Vaccine | II | Breast Cancer |
| Genentech, Inc. | Herceptin with Etoposide | II | Breast Cancer |
| Genentech, Inc. | Herceptin with Gemcitabine | II | Breast Cancer |
| Genentech, Inc. | Herceptin with Paclitaxel | II | Breast Cancer |
| Genentech, Inc. | Herceptin with Taxotere | II | Breast Cancer |
| Genentech, Inc. | Ixabepilone with Carboplatin and Trastuzumab | II | Breast Cancer |
| Regulon, Inc | Lipoplatin with Docetaxel | II | Breast Cancer |
| Regulon, Inc | Lipoplatin with Navelbine (First Line Therapy) | II | Breast Cancer |
| Genentech, Inc. | LY317615 with Avastin and Paclitaxel | II | Breast Cancer |
| HERMES Biosciences | Nanoliposomal vinorelbine | II | Breast Cancer |
| Onyx Pharmaceuticals Inc w/ Bayer Healthcare Pharmaceuticals | Nexavar | II | Breast Cancer |
| Onyx Pharmaceuticals Inc | Nexavar with Aromatase inhibitor (First/Second Line) | II | Breast Cancer |
| Onyx Pharmaceuticals Inc | Nexavar with Capecitabine | II | Breast Cancer |
| Onyx Pharmaceuticals Inc | Nexavar with Docetaxel and Letrozole | II | Breast Cancer |
| Onyx Pharmaceuticals Inc w/ Bayer Healthcare Pharmaceuticals | Nexavar with Gemcitabine | II | Breast Cancer |
| Onyx Pharmaceuticals Inc | Nexavar with Paclitaxel (First Line) | II | Breast Cancer |
| Nektar Therapeutics | NKTR102 | II | Breast Cancer |
| NuRx Pharmaceuticals, Inc | NRX4204 | II | Breast Cancer |
| Isis Pharmaceuticals Inc | OGX011 with Docetaxel (Second Line Therapy) | II | Breast Cancer |
| Optimer Pharmaceuticals, Inc. | OPT822 with OPT821 | II | Breast Cancer |
| Genentech, Inc. | R3502 (Third Line Therapy) | II | Breast Cancer |
| Genentech, Inc. | R3502 with docetaxel (First Line Therapy) | II | Breast Cancer |
| Genentech, Inc. | R3502 with pertuzumab | II | Breast Cancer |
| Genentech, Inc. | Rapamycin with Herceptin | II | Breast Cancer |
| Epeius Biotechnologies Corp | Rexin-G | II | Breast Cancer |
| Cytokinetics Inc | SB715992 | II | Breast Cancer |
| Genentech, Inc. | Tarceva | II | Breast Cancer |
| Genentech, Inc. | Tarceva with Chemotherapy | II | Breast Cancer |
| Telik Inc | Telcyta | II | Breast Cancer |
Cancer
A cancer is generally defined as the uncontrollable growth and replication of cells. This can occur virtually anywhere in the body, in any tissue or organ. Cancer grows out of normal cells in the body. Normal cells multiply when the body needs them and die when the body doesn't. Cancer appears to occur when the growth of cells in the body is out of control and cells divide too rapidly. It can also occur when cells “forget” how to die. According to the American Cancer Society, 7.6 million people died of cancer in the world in 2007.
| Company | Product | Phase | |
| Monogram Biosciences Inc | ACLARA's eTag Assay System | M | Cancer |
| Amdl Inc | Docetaxel AMDL INC | M | Cancer |
| Valeant Pharmaceuticals International | Fluorouracil | M | Cancer |
| SciClone Pharmaceuticals Inc | Zadaxin | M | Metastatic Cancer |
| Watson Pharmaceuticals Inc | Irinotecan Hydrochloride | M | Cancer |
| Amgen Inc | AMG162 | III | Bone Metastases |
| Genentech, Inc. | Avastin | III | Cancer |
| Applied Protein Sciences, LLC | AP001 | II | Cancer |
| Genentech, Inc. | Avastin with Capecitabine and Radiotherapy | II | Cancer |
| Genentech, Inc. | Avastin with Erlotinib | II | Cancer |
| Genentech, Inc. | Avastin with Gemcitabine, Oxaliplatin | II | Cancer |
| Genentech, Inc. | Avastin with Oxaliplatin | II | Cancer |
| Genentech, Inc. | Avastin with Paclitaxel | II | Cancer |
| Genentech, Inc. | Avastin with RAD001 | II | Cancer |
| Genentech, Inc. | Avastin with Tarceva, Capecitabine | II | Cancer |
| Genentech, Inc. | Avastin, 5-Fluorouracil and Radiation with Modified FOLFOX6 | II | Cancer |
| Genentech, Inc. | Avastin, Erlotinib with Paclitaxel, Carboplatin | II | Cancer |
| BiPar Sciences Inc | BSI-201 with Carboplatin, Paclitaxel | II | Cancer |
| SuperGen Inc | Campath, Pentostatin | II | Cancer |
| Tragara Pharmaceuticals, Inc. | Capoxigem | II | Cancer |
| Genentech, Inc. | Carboplatin with Avastin and Alimta (First Line Therapy) | II | Cancer |
| Genentech, Inc. | LBH589 with Tarceva | II | Cancer |
| Regulon, Inc | Lipoxal | II | Cancer |
| Onyx Pharmaceuticals Inc | ONX0803 | II | Cancer |
| Rigel Pharmaceuticals Inc | R788 | II | Cancer |
| Genentech, Inc. | RAD001 with Tarceva | II | Cancer |
| Ardea Biosciences, Inc. | RDEA119 with Nexavar | II | Cancer |
| Genentech, Inc. | Tarceva | II | Cancer |
| Nektar Therapeutics | NKTR102 | II | Cervical Cancer |
Chemotherapy- and Radiotherapy-Induced Side Effects
Cancer is often treated with a chemotherapy and/or radiotherapy. Radiation and chemotherapy, unfortunately, often bring with them a variety of side effects ranging from hair loss and appetite changes to decreased general immune function. Current treatments and concomitant supportive care medications may lessen the severity and occurrences of these effects.
| Company | Product | Phase | |
| BioPro Pharmaceutical, Inc. | Fentanyl | PA | Chemotherapy-induced Side Effects |
| Amgen Inc | Prolia | PA | Chemotherapy-induced Side Effects |
| Pharmagenesis Inc | Injectable Astragalus Polysaccharide | M | Chemotherapy-induced Side Effects |
| Watson Pharmaceuticals Inc | Fentanyl Citrate | M | Chemotherapy-induced Side Effects |
| Novartis AG | Cardioxane (dexrazoxane) | M | Chemotherapy-induced Side Effects |
| Valeant Pharmaceuticals International | Cesamet | M | Chemotherapy-induced Side Effects |
| Watson Pharmaceuticals Inc | Dronabinol | M | Chemotherapy-induced Side Effects |
| Spectrum Pharmaceuticals Inc | Fusilev | M | Chemotherapy-induced Side Effects |
| Spectrum Pharmaceuticals Inc | Fusilev | M | Chemotherapy-induced Side Effects |
| Amgen Inc | Neupogen | M | Chemotherapy-induced Side Effects |
| Amdl Inc | Ondansetron hydrochloride | M | Chemotherapy-induced Side Effects |
| AP Pharma Inc | APF530 | II | Chemotherapy-induced Side Effects |
| Pharmagenesis Inc | Xuebao | II | Chemotherapy-induced Side Effects |
| Applied Protein Sciences, LLC | AP001 | II | Chemotherapy-induced Side Effects |
| Maxygen Inc | MaxyG34 | II | Chemotherapy-induced Side Effects |
| Amgen Inc | Nplate | II | Chemotherapy-induced Side Effects |
| Ligand Pharmaceuticals Inc | Promacta | II | Chemotherapy-induced Side Effects |
| SciClone Pharmaceuticals Inc | SCV07 | II | Chemotherapy-induced Side Effects |
| Telik Inc | Telintra | II | Chemotherapy-induced Side Effects |
Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia (CLL) occurs later in life and is a malignancy of the lymphocyte. CLL cells grow uncontrollably in the bone marrow, causing an increased concentration of those cells in the blood. The CLL cells do not affect normal blood cell production as is the case in other forms of leukemia, lessening the symptoms in the early stages of the disease. According to the Leukemia-Lymphoma Society, nearly 10,020 people are diagnosed with chronic lymphocytic leukemia in the U.S. each year, most of whom are over 50 years old at the time of diagnosis.
| Company | Product | Phase | |
| SuperGen Inc | Nipent with Cytoxan and Rituxan | PM | Chronic Lymphocytic Leukemia |
| Genentech Inc | Rituxan with chemotherapy | III | Chronic Lymphocytic Leukemia |
| Genentech Inc | ABT263 | II | Chronic Lymphocytic Leukemia |
| Genentech Inc | Anti-CD20 (III Generation) | II | Chronic Lymphocytic Leukemia |
| Cylene Pharmaceuticals, Inc. | CX3543 | II | Chronic Lymphocytic Leukemia |
| Genentech, Inc. | GA101 | II | Chronic Lymphocytic Leukemia |
| Geron Corp | GRN163L | II | Chronic Lymphocytic Leukemia |
| Tragen Pharmaceuticals | ISF154 | II | Chronic Lymphocytic Leukemia |
| Facet Biotech Corporation | TRU016 | II | Chronic Lymphocytic Leukemia |
| Pharmacyclics Inc | Xcytrin | II | Chronic Lymphocytic Leukemia |
Chronic Myelogenous Leukemia
Chronic myelogenous leukemia, also called CML, is a disease in which the bone marrow makes too many white blood cells. CML is a slowly progressing blood and bone marrow disease that usually occurs during or after middle age, and rarely occurs in children. Normally, the bone marrow makes blood stem cells (immature cells) that develop into mature blood cells over time. A blood stem cell may become a myeloid stem cell or a lymphoid stem cell. The lymphoid stem cell develops into a white blood cell. The National Cancer Institute estimates that about 4,830 new cases are diagnosed each year in the U.S.
Colon Cancer/ Colorectal Cancer
Colorectal cancer starts either in the large intestine (colon) or in the rectum (end of the colon). The most common form is called adenocarcinoma of the colon. Research shows that most colorectal cancers start as benign polyps, which over a period of many years develop into cancers. Other factors that contribute are ulcerative colitis, a family history of colon cancer and a high-meat, high-fat, low-fiber diet. The National Cancer Institute estimated 148,810 new cases of colon and rectal cancer in 2008.
| Company | Product | Phase | |
| Spectrum Pharmaceuticals Inc | Fusilev with 5-Fluorouracil-based chemotherapy | PA | Colorectal Cancer |
| Genentech Inc | Avastin with Fluorouracil Based Chemotherapy | M | Colorectal Cancer |
| Amgen Inc | Vectibix | M | Colorectal Cancer |
| Genentech, Inc. | Avastin with XELOX or FOLFOX | III | Colorectal Cancer |
| Genentech, Inc. | Xelox | III | Colorectal Cancer |
| Genentech, Inc. | Avastin (Second Line Therapy) | III | Colorectal Cancer |
| Genentech, Inc. | Avastin with Chemotherapy and Tarceva | III | Colorectal Cancer |
| Amgen Inc | Vectibix with FOLFIRI (Second Line Therapy) | III | Colorectal Cancer |
| Amgen Inc | Vectibix with FOLFOX | III | Colorectal Cancer |
| Genomic Health Inc | Colon Cancer Diagnostic | II | Colorectal Cancer |
| Jennerex Biotherapeutics, Inc. | JX594 | II | Colorectal Cancer |
| Genentech Inc | ABT869 | II | Colorectal Cancer |
| Poniard Pharmaceuticals Inc | AMD473 with 5-fluorouracil and Leucovorin (First Line Therapy) | II | Colorectal Cancer |
| Amgen Inc | AMG102 with Panitumumab | II | Colorectal Cancer |
| Amgen Inc | AMG386 with FOLFIRI | II | Colorectal Cancer |
| Amgen Inc | AMG479 with Panitumumab | II | Colorectal Cancer |
| Amgen Inc | AMG655 with mFOLFOX6 and Bevacizumab (First-Line Therapy) | II | Colorectal Cancer |
| Amgen Inc | AMG655 with Panitumumab | II | Colorectal Cancer |
| Actis Biologics, Inc. | Angiozyme | II | Colorectal Cancer |
| Genentech, Inc. | Avastin with Capecitabine and Oxaliplatin (First Line Therapy) | II | Colorectal Cancer |
| Genentech, Inc. | Avastin with RAD001 | II | Colorectal Cancer |
| Genentech, Inc. | Avastin with Tarceva, FOLFOX | II | Colorectal Cancer |
| Genentech, Inc. | Avastin with Xeloda | II | Colorectal Cancer |
| ACT Biotech, Inc. | BAY579352 (Second Line) | II | Colorectal Cancer |
| Genentech, Inc. | GDC0449 with Bevacizumab and Chemotherapy (First Line Therapy) | II | Colorectal Cancer |
| Onyx Pharmaceuticals Inc w/ Bayer Healthcare Pharmaceuticals | Nexavar | II | Colorectal Cancer |
| Onyx Pharmaceuticals Inc | Nexavar with mFOLFOX6 | II | Colorectal Cancer |
| Nektar Therapeutics | NKTR102 | II | Colorectal Cancer |
| Nektar Therapeutics | NKTR102 with Cetuximab (Second Line Therapy) | II | Colorectal Cancer |
| SuperGen Inc | Orathecin | II | Colorectal Cancer |
| HERMES Biosciences | PEP02 with 5-Flourouracil and leucovorin | II | Colorectal Cancer |
| Cytokinetics Inc | SB715992 (Second Line Therapy) | II | Colorectal Cancer |
| Genentech, Inc. | Tarceva with Chemotherapy | II | Colorectal Cancer |
| Genentech, Inc. | Tarceva with Oxaliplatin and Capecitabine | II | Colorectal Cancer |
| Telik Inc | Telcyta | II | Colorectal Cancer |
| Amgen Inc | Vectibix with FOLFIRI (First Line Therapy) | II | Colorectal Cancer |
Esophageal Cancer
Esophageal cancer forms in tissues lining the esophagus, the muscular tube through which food passes from the throat to the stomach. Two types of esophageal cancer are squamous cell carcinoma (cancer that begins in flat cells lining the esophagus) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Very small tumors in the esophagus usually do not cause symptoms. As a tumor grows, the most common symptom is difficulty in swallowing. The National Cancer Institute estimated 16,470 new cases in 2008.
| Company | Product | Phase | |
| Genentech, Inc. | Avastin with Chemoradiation | II | Esophageal Cancer |
| Genentech, Inc. | Avastin with Modified DCF | II | Esophageal Cancer |
| Genentech, Inc. | Avastin, Tarceva with Chemotherapy, Radiotherapy | II | Esophageal Cancer |
Gastrointestinal Cancer
Gastrointestinal cancer refers to cancer which forms within the gastrointestinal tract, somewhere in the esophagus, stomach, liver, biliary system, pancreas, bowels, or anus. Several risk factors for developing gastrointestinal cancer have been identified. The frequency of gastrointestinal tumors increases with each decade of life and these tumors occur somewhat more frequently in men than in women. Persons of Asian, Pacific Islander, Hispanic and African American descent have a statistically higher chance of developing the cancer compared to non-Hispanic white Americans. Additionally, eating smoked, salted or pickled foods may lead to an increased risk, whereas eating fresh fruits and vegetables lowers the risk. Also, as with several other cancers, cigarette smokers tend to have increased rates of stomach cancers.
| Company | Product | Phase | |
| Genentech, Inc. | Avastin | III | Gastrointestinal (Stomach) Cancer |
| Genentech, Inc. | Avastin with Xeloda and Cisplatin (First Line Therapy) | III | Gastrointestinal (Stomach) Cancer |
| Amgen Inc | AMG102 with Epirubicin, Cisplatin and Capecitabine (First Line Therapy) | II | Gastrointestinal (Stomach) Cancer |
| Amgen Inc | AMG386 | II | Gastrointestinal (Stomach) Cancer |
| Amgen Inc | AMG706 | II | Gastrointestinal (Stomach) Cancer |
| Genentech, Inc. | Avastin with Capecitabine and Carboplatin | II | Gastrointestinal (Stomach) Cancer |
| Genentech, Inc. | Avastin with Capecitabine, Oxaliplatin and Radiation Therapy | II | Gastrointestinal (Stomach) Cancer |
| Genentech, Inc. | Avastin with Docetaxel, Cisplatin and Irinotecan | II | Gastrointestinal (Stomach) Cancer |
| Genentech, Inc. | Avastin with FOLFOX | II | Gastrointestinal (Stomach) Cancer |
| Genentech, Inc. | Avastin with Taxotere | II | Gastrointestinal (Stomach) Cancer |
| Genentech, Inc. | Avastin with Xelox | II | Gastrointestinal (Stomach) Cancer |
| ACT Biotech, Inc. | BAY579352 (First Line) | II | Gastrointestinal (Stomach) Cancer |
| ACT Biotech, Inc. | BAY579352 (Second Line) | II | Gastrointestinal (Stomach) Cancer |
| Regulon, Inc | Lipoplatin with Radiotherapy, 5-Fluorouracil | II | Gastrointestinal (Stomach) Cancer |
| Regulon, Inc | Lipoxal | II | Gastrointestinal (Stomach) Cancer |
| Onyx Pharmaceuticals Inc | Nexavar | II | Gastrointestinal (Stomach) Cancer |
| Onyx Pharmaceuticals Inc | Nexavar with Docetaxel and Cisplatin | II | Gastrointestinal (Stomach) Cancer |
| SuperGen Inc | Orathecin | II | Gastrointestinal (Stomach) Cancer |
| HERMES Biosciences | PEP02 | II | Gastrointestinal (Stomach) Cancer |
| Genentech, Inc. | Tarceva with FOLFOX6 | II | Gastrointestinal (Stomach) Cancer |
| Exelixis Inc | XL880 | II | Gastrointestinal (Stomach) Cancer |
Head and Neck Cancer
Most head and neck cancers begin in the mucous linings in the head and neck, such as the sinuses, mouth and larynx. Symptoms of such a cancer usually include a lump or sore that does not heal, a persistent sore throat, difficulty swallowing and a change of hoarseness in the voice. As many as 90 percent of head and neck cancers arise after prolonged exposure to specific factors including tobacco (cigarettes, cigars, chewing tobacco or snuff) and/or alcoholic beverages. Prolonged exposure to sunlight is linked with cancer of the lip and is also a major cause of skin cancer. There were about 40,490 new cases in 2006.
| Company | Product | Phase | |
| Genentech, Inc. | Avastin | III | Head and Neck Cancer |
| Regulon, Inc | Lipoplatin with fluorouracil | III | Head and Neck Cancer |
| Genentech, Inc. | Tarceva | III | Head and Neck Cancer |
| Amgen Inc | Vectibix | III | Head and Neck Cancer |
| Abraxis BioScience, Inc. | Abraxane with Carboplatin, Erbitux and IMRT | II | Head and Neck Cancer |
| Genentech, Inc. | Alimta with Avastin | II | Head and Neck Cancer |
| Genentech, Inc. | Avastin with Tarceva | II | Head and Neck Cancer |
| Genentech, Inc. | Avastin with Tarceva and Radiation | II | Head and Neck Cancer |
| Genentech, Inc. | Avastin with Tarceva, Chemotherapy and Radiation Therapy | II | Head and Neck Cancer |
| Regulon, Inc | Lipoplatin with Radiation | II | Head and Neck Cancer |
| Onyx Pharmaceuticals Inc | Nexavar with Carboplatin and Paclitaxel | II | Head and Neck Cancer |
| Cytokinetics Inc | SB715992 (First or Second Line Therapy) | II | Head and Neck Cancer |
| Genentech, Inc. | Tarceva | II | Head and Neck Cancer |
| Genentech, Inc. | Tarceva with Bevacizumab or Sulindac | II | Head and Neck Cancer |
| Genentech, Inc. | Tarceva with Docetaxel and Cisplatin | II | Head and Neck Cancer |
| Genentech, Inc. | Tarceva with RADPLAT | II | Head and Neck Cancer |
| Exelixis Inc | XL880 | II | Head and Neck Cancer |
Hematological Malignancies
Hematological malignancies are the types of cancer that affect blood, bone marrow and lymph nodes. As the three are intimately connected through the immune system, a disease affecting one of the three will often affect the others as well: although lymphoma is technically a disease of the lymph nodes, it often spreads to the bone marrow, affecting the blood and occasionally producing a paraprotein.
| Company | Product | Phase | |
| Amgen Inc | Aranesp with Venofer | III | Hematological Malignancies |
| Amgen Inc | StemEx | III | Hematological Malignancies |
| Gilead Sciences Inc | GS9219 | II | Hematological Malignancies |
| SuperGen Inc | Myelosuppressive Regimen with Pentostatin and Low-Dose Total Body | II | Hematological Malignancies |
| TargeGen Inc | TG101348 | II | Hematological Malignancies |
Hodgkin's Lymphoma
Cancer of the immune system that is marked by the presence of a type of cell called the Reed-Sternberg cell, Hodgkin’s Lymphoma is categorized into two types. Hodgkin lymphoma are classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma. Symptoms include the painless enlargement of lymph nodes, spleen, or other immune tissue. The National Cancer Institute estimated 8,220 new cases in 2008.
| Company | Product | Phase | |
| Genentech, Inc. | Avastin with ABVD | II | Hodgkin Lymphoma |
| Genentech, Inc. | Rituxan with ABVD | II | Hodgkin Lymphoma |
| Cytokinetics Inc | SB743921 | II | Hodgkin Lymphoma |
| Genentech, Inc. | TNX650 | II | Hodgkin Lymphoma |
Kidney Cancer
Kidney cancer in adults and children are different and distinct. Kidney cancer includes renal cell carcinoma (cancer that forms in the lining of very small tubes in the kidney that filter the blood and remove waste products) and renal pelvis carcinoma (cancer that forms in the center of the kidney where urine collects). It also includes Wilms tumor, which is a type of kidney cancer that usually develops in children under the age of 5. According to the National Cancer Institute, there were about 54,390 new cases in 2008.
| Company | Product | Phase | |
| Johnson & Johnson | Doxil / Caelyx (pegylated liposomal doxorubicin hydrochloride) | M | Kaposi Sarcoma |
| Onyx Pharmaceuticals Inc w/ Bayer Healthcare Pharmaceuticals | Nexavar | M | Kidney Cancer |
| Novartis AG | Proleukin (aldesleukin) | M | Kidney Cancer |
| Onyx Pharmaceuticals Inc w/ Bayer Healthcare Pharmaceuticals | Nexavar with Sunitinib | III | Kidney Cancer |
| Genentech Inc | ABT869 | II | Kidney Cancer |
| Amgen Inc | AMG102 | II | Kidney Cancer |
| Amgen Inc | AMG386 | II | Kidney Cancer |
| Amgen Inc | AMG386 with Sunitinib | II | Kidney Cancer |
| Genentech, Inc. | Avastin | II | Kidney Cancer |
| Genentech, Inc. | Avastin with Gemcitabine and Capecitabine | II | Kidney Cancer |
| Genentech, Inc. | Avastin with RAD001 | II | Kidney Cancer |
| Genentech, Inc. | Avastin with Temsirolimus | II | Kidney Cancer |
| Genentech, Inc. | Avastin, Tarceva with Gleevec | II | Kidney Cancer |
| Onyx Pharmaceuticals Inc | Nexavar with Gemcitabine and Capecitabine | II | Kidney Cancer |
| Onyx Pharmaceuticals Inc | Nexavar with Interferon | II | Kidney Cancer |
| Cytokinetics Inc | SB715992 (Second Line Therapy) | II | Kidney Cancer |
| Genentech, Inc. | Tarceva with Rapamune | II | Kidney Cancer |
| Amgen Inc | Vectibix | II | Kidney Cancer |
| VasGene Therapeutics Inc | Veglin with IL-2 | II | Kidney Cancer |
| Pharmacyclics Inc | Xcytrin | II | Kidney Cancer |
| Exelixis Inc | XL880 | II | Kidney Cancer |
| SuperGen Inc | Orathecin | II | Sarcoma |
| Pharmacyclics Inc | PCI24781 with Doxorubicin | II | Sarcoma |
| Threshold Pharmaceuticals Inc | TH302 with Doxorubicin | II | Sarcoma |
| Genentech Inc | Avastin with interferon alfa-2a | A | Kidney Cancer |
Liver Cancer
Primary liver cancer is cancer that forms in the tissues of the liver. Secondary liver cancer is cancer that spreads to the liver from another part of the body. The most common primary liver cancer in adults is called hepatoma or hepatocellular carcinoma (HCC). In addition, tumors that originate elsewhere in the body (e.g. colon or breast) frequently metastasize to the liver. Liver cancer has the fastest growing death rate amongst all cancers in the U.S. Most liver cancer in the U.S. and globally is secondary to chronic viral hepatitis, both chronic hepatitis B and chronic hepatitis C. There were 21,370 new cases in 2008 according to the National Cancer Institute.
| Company | Product | Phase | |
| SciClone Pharmaceuticals Inc | DC Bead | II | Liver Cancer |
| Onyx Pharmaceuticals Inc w/ Bayer Healthcare Pharmaceuticals | Nexavar | II | Liver Cancer |
| Onyx Pharmaceuticals Inc | Nexavar with Tarceva | II | Liver Cancer |
| SciClone Pharmaceuticals Inc | Zadaxin | II | Liver Cancer |
| Genentech Inc | ABT869 | II | Liver Cancer |
| Polaris Group | ADI PEG 20 | II | Liver Cancer |
| Cougar Biotechnology, Inc. | CB1089 | II | Liver Cancer |
| Jennerex Biotherapeutics Inc | JX594 | II | Liver Cancer |
| Metabasis Therapeutics Inc | MB07133 | II | Liver Cancer |
| Onyx Pharmaceuticals Inc | Nexavar | II | Liver Cancer |
| Onyx Pharmaceuticals Inc w/ Bayer Healthcare Pharmaceuticals | Nexavar with Doxorubicin | II | Liver Cancer |
| Proacta Inc | PR104 with sorafenib | II | Liver Cancer |
| Cytokinetics Inc | SB715992 (First Line Therapy) | II | Liver Cancer |
| Genentech, Inc. | Tarceva with Avastin | II | Liver Cancer |
Lung Cancer
Lung cancer is a cancerous growth in lung tissue, lung cancer may be metastatic from another source or may be primary (tumor is of lung cell origin). The two main types are small cell lung cancer and non-small cell lung cancer. These types are diagnosed based on how the cells look under a microscope. The National Cancer Institute estimated 215,020 new cases in 2008.
| Company | Product | Phase | |
| Genentech, Inc. | Tarceva with Chemotherapy (First Line Therapy) | PA | Non-Small-Cell Lung Cancer |
| Genentech Inc | Avastin with Carboplatin and Paclitaxel | M | Non-Small-Cell Lung Cancer |
| Genentech Inc | Tarceva | M | Non-Small-Cell Lung Cancer |
| MaxoCore Pharmaceuticals Inc | SRXMs with chemotherapy | III | Non-Small-Cell Lung Cancer |
| Abraxis BioScience Inc | Abraxane | III | Non-Small-Cell Lung Cancer |
| Abraxis BioScience Inc | Abraxane with Carboplatin | III | Non-Small-Cell Lung Cancer |
| Amgen Inc | AMG706 | III | Non-Small-Cell Lung Cancer |
| Genentech, Inc. | Avastin with Gemcitabine and Cisplatin (First Line Therapy) | III | Non-Small-Cell Lung Cancer |
| Genentech Inc | Avastin with Tarceva (First Line Therapy) | III | Non-Small-Cell Lung Cancer |
| Regulon, Inc | Lipoplatin with gemcitabine | III | Non-Small-Cell Lung Cancer |
| Regulon, Inc | Lipoplatin with Paclitaxel (First Line Therapy) | III | Non-Small-Cell Lung Cancer |
| NovaRx Corp | Lucanix | III | Non-Small-Cell Lung Cancer |
| Onyx Pharmaceuticals Inc | Nexavar | III | Non-Small-Cell Lung Cancer |
| Onyx Pharmaceuticals Inc | Nexavar with Carboplatin and Paclitaxel | III | Non-Small-Cell Lung Cancer |
| Onyx Pharmaceuticals Inc | Nexavar with Cisplatin and Gemcitabine (First Line Therapy) | III | Non-Small-Cell Lung Cancer |
| Genentech Inc | Tarceva with Avastin (First Line Therapy) | III | Non-Small-Cell Lung Cancer |
| Genentech Inc | Tarceva with Avastin (Second Line Therapy) | III | Non-Small-Cell Lung Cancer |
| Genentech, Inc. | Tarceva with Docetaxel, Carboplatin and Thoracic Radiotherapy | III | Non-Small-Cell Lung Cancer |
| Telik Inc | Telcyta | III | Non-Small-Cell Lung Cancer |
| Telik Inc | Telcyta with Gefitinib (Third Line Therapy) | III | Non-Small-Cell Lung Cancer |
| Poniard Pharmaceuticals Inc | Picoplatin | III | Small Cell Lung Cancer |
| HERMES Biosciences | Nanoliposomal irinotecan | II | Lung Cancer |
| HERMES Biosciences | Nanoliposomal vinorelbine | II | Lung Cancer |
| MaxoCore Pharmaceuticals Inc | SRXMs with EGFR inhibitors | II | Lung Cancer |
| Genentech Inc | Tarceva | II | Lung Cancer |
| Genentech Inc | ABT869 | II | Non-Small-Cell Lung Cancer |
| Genentech, Inc. | ABT869 with Paclitaxel and Carboplatin (First Line Therapy) | II | Non-Small-Cell Lung Cancer |
| Genentech, Inc. | Alimta, Gemzar with Avastin (First Line Therapy) | II | Non-Small-Cell Lung Cancer |
| Amgen Inc | AMG655 | II | Non-Small-Cell Lung Cancer |
| Genentech Inc | Apomab with Avastin, Carboplatin and Paclitaxel | II | Non-Small-Cell Lung Cancer |
| Genentech Inc | Avastin | II | Non-Small-Cell Lung Cancer |
| Genentech, Inc. | Avastin with Carboplatin and Gemcitabine (First Line Therapy) | II | Non-Small-Cell Lung Cancer |
| Genentech, Inc. | Avastin with Carboplatin, and Abraxane | II | Non-Small-Cell Lung Cancer |
| Abraxis BioScience, Inc. | Avastin with Carboplatin, and Abraxane | II | Non-Small-Cell Lung Cancer |
| Genentech, Inc. | Avastin with Carboplatin, Docetaxel and Erlotinib | II | Non-Small-Cell Lung Cancer |
| Genentech, Inc. | Avastin with Chemotherapy | II | Non-Small-Cell Lung Cancer |
| Genentech, Inc. | Avastin with Docetaxel and Carboplatin | II | Non-Small-Cell Lung Cancer |
| Genentech, Inc. | Avastin with Gemcitabine and Carboplatin | II | Non-Small-Cell Lung Cancer |
| Genentech, Inc. | Avastin with Gemcitabine, Oxaliplatin (First Line Therapy) | II | Non-Small-Cell Lung Cancer |
| Genentech, Inc. | Avastin with Pemetrexed, Carboplatin and Enzastaurin | II | Non-Small-Cell Lung Cancer |
| Genentech, Inc. | Avastin with Pemetrexed, Carboplatin and Radiotherapy | II | Non-Small-Cell Lung Cancer |
| Genentech, Inc. | Avastin with Tarceva | II | Non-Small-Cell Lung Cancer |
| Peregrine Pharmaceuticals Inc | Bavituximab with Chemotherapy | II | Non-Small-Cell Lung Cancer |
| BiPar Sciences Inc | BSI-201 with Carboplatin, Paclitaxel | II | Non-Small-Cell Lung Cancer |
| Nektar Therapeutics | CDP791 | II | Non-Small-Cell Lung Cancer |
| Genentech, Inc. | Docetaxel and Oxaliplatin with Avastin (First Line Therapy) | II | Non-Small-Cell Lung Cancer |
| Genentech, Inc. | Eloxatin with Alimta and Bevacizumab | II | Non-Small-Cell Lung Cancer |
| Threshold Pharmaceuticals Inc | Glufosfamide | II | Non-Small-Cell Lung Cancer |
| Genentech, Inc. | Ixabepilone, Carboplatin with Avastin | II | Non-Small-Cell Lung Cancer |
| Regulon, Inc | Lipoplatin | II | Non-Small-Cell Lung Cancer |
| Regulon, Inc | Lipoplatin with Lipoxal and Docetaxel | II | Non-Small-Cell Lung Cancer |
| Facet Biotech Corporation | M200 | II | Non-Small-Cell Lung Cancer |
| Genentech, Inc. | MetMAb with Tarceva | II | Non-Small-Cell Lung Cancer |
| Genentech, Inc. | Metronomic Chemotherapy with Avastin | II | Non-Small-Cell Lung Cancer |
| Onyx Pharmaceuticals Inc | Nexavar with Pemetrexed disodium (Second Line) | II | Non-Small-Cell Lung Cancer |
| Onyx Pharmaceuticals Inc | Nexavar with Tarceva | II | Non-Small-Cell Lung Cancer |
| Nereus Pharmaceuticals, Inc. | NPI2358 with docetaxel | II | Non-Small-Cell Lung Cancer |
| NuRx Pharmaceuticals, Inc | NRX4204 | II | Non-Small-Cell Lung Cancer |
| NuRx Pharmaceuticals, Inc | NRX5183 | II | Non-Small-Cell Lung Cancer |
| Isis Pharmaceuticals Inc | OGX011 with Gemcitabine, Cisplatin (First Line Therapy) | II | Non-Small-Cell Lung Cancer |
| Genentech, Inc. | Omnitarg with Tarceva (Second Line Therapy) | II | Non-Small-Cell Lung Cancer |
| SuperGen Inc | Orathecin | II | Non-Small-Cell Lung Cancer |
| Proacta Inc | PR104 with Docetaxel | II | Non-Small-Cell Lung Cancer |
| Amgen Inc | rhApo2L/TRAIL with Avastin (First Line Therapy) | II | Non-Small-Cell Lung Cancer |
| Genentech Inc | rhApo2L/TRAIL with Avastin (First Line Therapy) | II | Non-Small-Cell Lung Cancer |
| Spectrum Pharmaceuticals Inc | Satraplatin with Taxol | II | Non-Small-Cell Lung Cancer |
| Cytokinetics Inc | SB715992 | II | Non-Small-Cell Lung Cancer |
| Genentech, Inc. | Tarceva with Chemoradiation | II | Non-Small-Cell Lung Cancer |
| Genentech, Inc. | Tarceva with Targretin | II | Non-Small-Cell Lung Cancer |
| Genentech, Inc. | Taxotere with Carboplatin and Radiotherapy | II | Non-Small-Cell Lung Cancer |
| Telik Inc | Telcyta with Carboplatin, Paclitaxel | II | Non-Small-Cell Lung Cancer |
| Telik Inc | Telcyta with Cisplatin | II | Non-Small-Cell Lung Cancer |
| Telik Inc | Telcyta with Cisplatin (First Line Therapy) | II | Non-Small-Cell Lung Cancer |
| Telik Inc | Telcyta with Docetaxel | II | Non-Small-Cell Lung Cancer |
| Amgen Inc | Vectibix with AMG706 | II | Non-Small-Cell Lung Cancer |
| Amgen Inc | Vectibix with Chemotherapy | II | Non-Small-Cell Lung Cancer |
| Pharmacyclics Inc | Xcytrin | II | Non-Small-Cell Lung Cancer |
| Pharmacyclics Inc | Xcytrin with Alimta | II | Non-Small-Cell Lung Cancer |
| Pharmacyclics Inc | Xcytrin with Taxotere | II | Non-Small-Cell Lung Cancer |
| Exelixis Inc | XL147 with Erlotinib | II | Non-Small-Cell Lung Cancer |
| Exelixis Inc | XL184 with Erlotinib | II | Non-Small-Cell Lung Cancer |
| Exelixis Inc | XL765 with Erlotinib | II | Non-Small-Cell Lung Cancer |
| OXiGENE INC | Zybrestat with Bevacizumab, Paclitaxel and Carboplatin | II | Non-Small-Cell Lung Cancer |
| OXiGENE INC | Zybrestat with Concurrent Chemoradiotherapy | II | Non-Small-Cell Lung Cancer |
| OXiGENE INC | Zybrestat with Radiotherapy | II | Non-Small-Cell Lung Cancer |
| Genentech Inc | ABT263 | II | Small Cell Lung Cancer |
| Amgen Inc | AMG102 with Carboplatin/Etopiside | II | Small Cell Lung Cancer |
| Amgen Inc | AMG479 with Cisplatin | II | Small Cell Lung Cancer |
| Genentech Inc | Avastin | II | Small Cell Lung Cancer |
| Genentech, Inc. | Avastin with Chemotherapy | II | Small Cell Lung Cancer |
| Genentech, Inc. | Avastin with irinotecan and carboplatin | II | Small Cell Lung Cancer |
| Genentech, Inc. | Avastin with Irinotecan, Carboplatin and Radiation Therapy | II | Small Cell Lung Cancer |
| Genentech, Inc. | Paclitaxel with Avastin | II | Small Cell Lung Cancer |
Melanoma (Skin Cancer)
Melanoma is a form of skin cancer that starts in the pigment-producing skin cells called melanocytes. These cells become abnormal, grow uncontrollably and aggressively invade surrounding tissues. Although melanoma is less common than other types of skin cancer, it is the by far the most serious. Damage to the genetic material (DNA) of melanocytes from sun exposure and UV light radiation is a major cause of melanoma. The National Cancer Institute estimated in 2008 that there were 62,480 new cases.
| Company | Product | Phase | |
| Novartis AG | Proleukin (aldesleukin) | M | Melanoma |
| North American Scientific Inc | Prospera | M | Melanoma |
| Valeant Pharmaceuticals International | Efudix | M | Skin Cancer |
| Abraxis BioScience Inc | Abraxane | III | Melanoma |
| Vical Inc | Allovectin-7 | III | Melanoma |
| SciClone Pharmaceuticals Inc | Zadaxin | III | Melanoma |
| Genentech, Inc. | Tarceva with Radiation Therapy | III | Melanoma |
| Genentech, Inc. | Abraxane with Bevacizumab (First Line Therapy) | II | Melanoma |
| Abraxis BioScience, Inc. | Abraxane with Bevacizumab (First Line Therapy) | II | Melanoma |
| Abraxis BioScience, Inc. | Abraxane with Carboplatin | II | Melanoma |
| Polaris Group | ADI PEG 20 | II | Melanoma |
| Attenuon LLC | ATN-224 with temozolomide | II | Melanoma |
| Genentech Inc | Avastin | II | Melanoma |
| Genentech, Inc. | Avastin with Carboplatin and Paclitaxel (First Line Therapy) | II | Melanoma |
| Amgen Inc | CR011-vcMMAE | II | Melanoma |
| Cytokinetics Inc | Ispinesib | II | Melanoma |
| Jennerex Biotherapeutics Inc | JX594 | II | Melanoma |
| PDL BioPharma Inc | M200 with Dacarbazine | II | Melanoma |
| Hana Biosciences Inc | Marqibo | II | Melanoma |
| MannKind Corp | MKC1106-MT | II | Melanoma |
| Genentech, Inc. | RAD001 with Avastin | II | Melanoma |
| Cytokinetics Inc | SB715992 (First Line Therapy) | II | Melanoma |
| Genentech, Inc. | GDC0449 | II | Skin Cancer |
| Genentech, Inc. | Tarceva | II | Skin Cancer |
Multiple Myeloma
Multiple myeloma is a malignancy of the plasma cells, a type of white blood cell. Myeloma begins when a plasma cell becomes abnormal. Myeloma cells collect in the bone marrow and may crowd out normal blood cells. Myeloma cells also collect in the solid part of the bone. The disease is called "multiple myeloma" because it affects many bones. The National Cancer Institute estimated 19,920 new cases in 2008.
| Company | Product | Phase | |
| Attenuon LLC | ATN-224 with bortezomib | II | Multiple Myeloma |
| Amgen Inc | Denosumab | II | Multiple Myeloma |
| Johnson & Johnson | Doxil (doxorubicin hydrochloride) | II | Multiple Myeloma |
| Amgen Inc | AMG162 | II | Multiple Myeloma |
| Genentech, Inc. | Avastin with Bortezomib | II | Multiple Myeloma |
| Cougar Biotechnology, Inc. | CB3304 | II | Multiple Myeloma |
| Facet Biotech Corporation | HuLuc63 with Velcade | II | Multiple Myeloma |
| Proteolix Inc | PR171 | II | Multiple Myeloma |
Non-Hodgkin’s Lymphoma
Non-Hodgkin lymphomas can occur at any age and are often marked by enlarged lymph nodes, fever, and weight loss. There are many different types of non-Hodgkin lymphoma, which can be divided into aggressive (fast-growing) and indolent (slow-growing) types and can be classified as either B-cell or T-cell non-Hodgkin lymphoma. B-cell non-Hodgkin lymphomas include Burkitt lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, and mantle cell lymphoma. T-cell non-Hodgkin lymphomas include mycosis fungoides, anaplastic large cell lymphoma, and precursor T-lymphoblastic lymphoma. Lymphomas related to lymphoproliferative disorders following bone marrow or stem cell transplantation are usually B-cell non-Hodgkin lymphomas. Prognosis and treatment depend on the stage and type of disease. Also called NHL. According to the National Cancer Institute, there were 66,120 new cases in 2008.
| Company | Product | Phase | |
| Genentech Inc | Rituxan | M | Non-Hodgkin Lymphoma |
| Genentech Inc | Rituxan with CHOP | M | Non-Hodgkin Lymphoma |
| Genentech Inc | Rituxan with CVP | M | Non-Hodgkin Lymphoma |
| Spectrum Pharmaceuticals Inc | Zevalin | M | Non-Hodgkin Lymphoma |
| Genentech, Inc. | MabThera with Avastin | III | Non-Hodgkin Lymphoma |
| Genitope Corp | MyVax personalized immunotherapy | III | Non-Hodgkin Lymphoma |
| Genitope Corp | MyVax personalized immunotherapy with Rituxan | III | Non-Hodgkin Lymphoma |
| Genentech Inc | Rituxan with Avastin | III | Non-Hodgkin Lymphoma |
| Genentech, Inc. | Rituxan with Chemotherapy | III | Non-Hodgkin Lymphoma |
| Spectrum Pharmaceuticals Inc | Zevalin with Rituxan | III | Non-Hodgkin Lymphoma |
| Geron Corporation | GRN163L | II | Lymphoma |
| XOMA Ltd | HCD122 | II | Lymphoma |
| Pharmacyclics Inc | PCI24781 | II | Lymphoma |
| Spectrum Pharmaceuticals Inc | Zevalin with R-FND | II | Lymphoma |
| Dynavax Technologies Corp | 1018 ISS with Rituxan | II | Non-Hodgkin Lymphoma |
| Genentech Inc | Apomab with Rituxan | II | Non-Hodgkin Lymphoma |
| Genentech, Inc. | Avastin with Rituxan | II | Non-Hodgkin Lymphoma |
| Genentech, Inc. | CC5103 with Rituximab | II | Non-Hodgkin Lymphoma |
| Genentech, Inc. | Chemotherapy, Rituxan with Pegfilgrastim, Rituxan | II | Non-Hodgkin Lymphoma |
| Amgen Inc | Chemotherapy, Rituxan with Pegfilgrastim, Rituxan | II | Non-Hodgkin Lymphoma |
| Genentech, Inc. | GA101 | II | Non-Hodgkin Lymphoma |
| Hana Biosciences Inc | Marqibo | II | Non-Hodgkin Lymphoma |
| SuperGen Inc | Nipent with Cytoxan and Rituxan | II | Non-Hodgkin Lymphoma |
| Amgen Inc | rhApo2L/TRAIL with Rituxan | II | Non-Hodgkin Lymphoma |
| Genentech Inc | rhApo2L/TRAIL with Rituxan | II | Non-Hodgkin Lymphoma |
| Genentech, Inc. | R-ICE Chemotherapy with SGN40 (Second Line Therapy) | II | Non-Hodgkin Lymphoma |
| Genentech, Inc. | Rituxan with Fludarabine | II | Non-Hodgkin Lymphoma |
| Genentech, Inc. | Rituxan with HCVAD | II | Non-Hodgkin Lymphoma |
| Cytokinetics Inc | SB743921 | II | Non-Hodgkin Lymphoma |
| Genentech, Inc. | SGN40 | II | Non-Hodgkin Lymphoma |
| Pharmacyclics Inc | Xcytrin | II | Non-Hodgkin Lymphoma |
| Spectrum Pharmaceuticals Inc | Zevalin with BEAM | II | Non-Hodgkin Lymphoma |
| Spectrum Pharmaceuticals Inc | Zevalin with Motexafin gadolinium | II | Non-Hodgkin Lymphoma |
| Novartis AG | Proleukin (aldesleukin) with Rituximab | II | Non-Hodgkin's Lymphoma |
Ovarian Cancer
Most ovarian cancers are either ovarian epithelial carcinomas (cancer that begins in the cells on the surface of the ovary) or malignant germ cell tumors (cancer that begins in egg cells). Women who have a family history of ovarian cancer are at an increased risk of developing ovarian cancer. Hereditary ovarian cancer makes up approximately 5 to 10 percent of all cases of ovarian cancer. Three hereditary patterns have been identified: ovarian cancer alone, ovarian and breast cancers and ovarian and colon cancers. Ovarian cancer is hard to detect early because there usually are no symptoms and those symptoms that do occur tend to be vague. The National Cancer Institute estimated 21,650 new cases in 2008
| Company | Product | Phase | |
| Johnson & Johnson | Doxil / Caelyx (pegylated liposomal doxorubicin hydrochloride) | M | Ovarian Cancer |
| Genentech, Inc. | Avastin (First Line Therapy) | III | Ovarian Cancer |
| Genentech, Inc. | Avastin (Second Line Therapy) | III | Ovarian Cancer |
| Genentech, Inc. | Avastin with Gemcitabine and Cisplatin | III | Ovarian Cancer |
| Genentech, Inc. | Tarceva | III | Ovarian Cancer |
| Telik Inc | Telcyta | III | Ovarian Cancer |
| Telik Inc | Telcyta with Carboplatin | III | Ovarian Cancer |
| Telik Inc | Telcyta with Doxil | III | Ovarian Cancer |
| Telik Inc | Telcyta with Doxorubicin (Second-Line Therapy) | III | Ovarian Cancer |
| Telik Inc | Telcyta with Doxorubicin, Topotecan (Third Line Therapy) | III | Ovarian Cancer |
| Abraxis BioScience Inc | Abraxane | II | Ovarian Cancer |
| Amgen Inc | AMG386 | II | Ovarian Cancer |
| Genentech, Inc. | Avastin with Abraxane | II | Ovarian Cancer |
| Abraxis BioScience, Inc. | Avastin with Abraxane | II | Ovarian Cancer |
| Genentech, Inc. | Avastin with Erlotinib | II | Ovarian Cancer |
| Genentech, Inc. | Avastin with Gemcitabine and Oxaliplatin | II | Ovarian Cancer |
| Genentech, Inc. | Avastin with Paclitaxel and Cisplatin | II | Ovarian Cancer |
| Genentech, Inc. | Avastin with Taxol and Carboplatin | II | Ovarian Cancer |
| BiPar Sciences Inc | BSI201 | II | Ovarian Cancer |
| BiPar Sciences, Inc. | BSI201 with Topotecan | II | Ovarian Cancer |
| Genentech, Inc. | Doxil with Avastin | II | Ovarian Cancer |
| Genentech, Inc. | GDC0449 | II | Ovarian Cancer |
| Facet Biotech Corporation | M200 | II | Ovarian Cancer |
| Facet Biotech Corporation | M200 with Doxorubicin | II | Ovarian Cancer |
| Onyx Pharmaceuticals Inc | Nexavar | II | Ovarian Cancer |
| Nektar Therapeutics | NKTR102 | II | Ovarian Cancer |
| Genentech Inc | Omnitarg with Gemcitabine | II | Ovarian Cancer |
| Cytokinetics Inc | SB715992 (Second Line Therapy) | II | Ovarian Cancer |
| Sunesis Pharmaceuticals Inc | SNS595 | II | Ovarian Cancer |
| Sunesis Pharmaceuticals Inc | Voreloxin | II | Ovarian Cancer |
| OXiGENE INC | Zybrestat with Paclitaxel and Carboplatin | II | Ovarian Cancer |
Pancreatic Cancer
Pancreatic cancer has been called a "silent" disease because early pancreatic cancer usually does not cause symptoms. If the tumor blocks the common bile duct and bile cannot pass into the digestive system, the skin and whites of the eyes may become yellow (jaundiced) and the urine darker as a result of accumulated bile pigment called bilirubin. Cancer of the pancreas has markedly increased in incidence over the decades and now ranks as the fourth leading cause of cancer death in the U.S. According to the National Cancer Institute, there were about 37,680 new cases in 2008
| Company | Product | Phase | |
| Genentech Inc | Tarceva with Gemcitabine | M | Pancreatic Cancer |
| Abraxis BioScience, Inc. | Abraxane with gemcitabine (First Line Therapy) | III | Pancreatic Cancer |
| Regulon, Inc | Lipoplatin with gemcitabine | III | Pancreatic Cancer |
| SuperGen Inc | Orathecin with Gemcitabine | III | Pancreatic Cancer |
| Amgen Inc | AMG655 | II | Pancreatic Cancer |
| Genentech, Inc. | Avastin and Tarceva with Radiation Therapy | II | Pancreatic Cancer |
| Genentech, Inc. | Avastin with 5-Fluorouracil, Oxaliplatin, Gemcitabine and External Beam Radiation Therapy | II | Pancreatic Cancer |
| Genentech, Inc. | Avastin with Gemcitabine and Oxaliplatin (First Line Therapy) | II | Pancreatic Cancer |
| Genentech, Inc. | Avastin, Gemcitabine with Radiation Therapy | II | Pancreatic Cancer |
| BiPar Sciences Inc | BSI-201 with Gemcitabine | II | Pancreatic Cancer |
| Tragara Pharmaceuticals, Inc. | Capoxigem with Gemcitabine and Erlotinib | II | Pancreatic Cancer |
| Threshold Pharmaceuticals Inc | Glufosfamide, Gemcitabine | II | Pancreatic Cancer |
| KangLaiTe USA Inc | Kanglaite with Gemcitabine | II | Pancreatic Cancer |
| Regulon, Inc | Lipoxal | II | Pancreatic Cancer |
| Facet Biotech Corporation | M200 with Gemcitabine | II | Pancreatic Cancer |
| Onyx Pharmaceuticals Inc | Nexavar | II | Pancreatic Cancer |
| Onyx Pharmaceuticals Inc w/ Bayer Healthcare Pharmaceuticals | Nexavar with Gemcitabine | II | Pancreatic Cancer |
| Advantagene Inc | PancAtak | II | Pancreatic Cancer |
Prostate Cancer
Prostate cancer is the most commonly diagnosed cancer among American men and is somewhat more common in African-American men than men of other racial origin. In the U.S., it is estimated that one out of every six men will develop prostate cancer. Changes in prostate cells contribute to the disease's development and progression. A breakdown in the cells' normal control mechanisms causes the development of cancer cells. The National Cancer Institute estimated 186,320 new cases in 2008
| Company | Product | Phase | |
| Watson Pharmaceuticals Inc | Trelstar | PA | Prostate Cancer |
| North American Scientific Inc | IoGold brachytherapy | M | Prostate Cancer |
| North American Scientific Inc | PdGold | M | Prostate Cancer |
| North American Scientific Inc | Prospera | M | Prostate Cancer |
| Watson Pharmaceuticals Inc | Trelstar Depot | M | Prostate Cancer |
| Watson Pharmaceuticals Inc | Trelstar LA | M | Prostate Cancer |
| BioPro Pharmaceutical Inc | Vantas | M | Prostate Cancer |
| Johnson & Johnson | Viadur (leuprolide acetate implant) | M | Prostate Cancer |
| Genentech Inc | Avastin | III | Prostate Cancer |
| Cougar Biotechnology Inc | CB7630 with Prednisone | III | Prostate Cancer |
| Medivation Inc | MDV3100 | III | Prostate Cancer |
| Spectrum Pharmaceuticals Inc | Orplatna with Prednisone | III | Prostate Cancer |
| Spectrum Pharmaceuticals Inc | Satraplatin with Prednisone | III | Prostate Cancer |
| Abraxis BioScience Inc | ABI008 | II | Prostate Cancer |
| Abraxis BioScience Inc | Abraxane | II | Prostate Cancer |
| Poniard Pharmaceuticals Inc | AMD473 with Docetaxel and Prednisone (First Line Therapy) | II | Prostate Cancer |
| Amgen Inc | AMG102 with Mitoxantrone and Prednisone | II | Prostate Cancer |
| Hollis-Eden Pharmaceuticals Inc | Apoptone | II | Prostate Cancer |
| Attenuon LLC | ATN224 | II | Prostate Cancer |
| Genentech, Inc. | Avastin with Docetaxel | II | Prostate Cancer |
| Genentech, Inc. | Avastin with Docetaxel, Androgen Deprivation | II | Prostate Cancer |
| Genentech, Inc. | Avastin with Hormonal and Radiotherapy | II | Prostate Cancer |
| Geron Corp | GRNVAC1 | II | Prostate Cancer |
| Isis Pharmaceuticals Inc | LY2181308 with Docetaxel and Prednisone | II | Prostate Cancer |
| Onyx Pharmaceuticals Inc | Nexavar | II | Prostate Cancer |
| Isis Pharmaceuticals Inc | OGX011 with Docetaxel and Prednisone (First Line Therapy) | II | Prostate Cancer |
| Isis Pharmaceuticals Inc | OGX011 with Docetaxel and Prednisone (Second Line Therapy) | II | Prostate Cancer |
| Isis Pharmaceuticals Inc | OGX011 with Hormone Ablation Therapy | II | Prostate Cancer |
| Spectrum Pharmaceuticals Inc | Ozarelix | II | Prostate Cancer |
| Poniard Pharmaceuticals Inc | Picoplatin | II | Prostate Cancer |
| Advantagene Inc | ProstAtak | II | Prostate Cancer |
| Inovio Biomedical Corporation | PSMA DNA Vaccine | II | Prostate Cancer |
| Genentech, Inc. | RAD001 with Docetaxel and Avastin | II | Prostate Cancer |
| Cytokinetics Inc | SB715992 (Second Line Therapy) | II | Prostate Cancer |
| Spectrum Pharmaceuticals Inc | SPI153 | II | Prostate Cancer |
Solid Tumors
Solid tumors are usually detected as a growth somewhere within the tissues of the body. These growths can either be malignant (cancerous) or benign (non-cancerous). Tumors are caused by the abnormal growth of cells often caused by damage to the cell’s DNA. Cancerous cells run the risk of spreading to other areas of the body and causing cancers in other tissues. Thus, once tumors are detected, they are generally surgically removed. Treatments focus on the suppression of tumor growth and metastasis (spreading).
| Company | Product | Phase | |
| Valeant Pharmaceuticals International | Fluorouracil VALEANT | M | Solid Tumors |
| SuperGen Inc | Orathecin | III | Solid Tumors |
| Ipsen Group | Somatuline Autogel | III | Solid Tumors |
| Ambit Biosciences Corporation | AC480 | II | Solid Tumors |
| Amgen Inc | AMG655 with AMG479 | II | Solid Tumors |
| Genentech, Inc. | Avastin with Temodar | II | Solid Tumors |
| Cylene Pharmaceuticals, Inc. | CX3543 | II | Solid Tumors |
| Spectrum Pharmaceuticals Inc | IDN5109 | II | Solid Tumors |
| Facet Biotech Corporation | M200 | II | Solid Tumors |
| Spectrum Pharmaceuticals Inc | Ortataxel | II | Solid Tumors |
| OXiGENE INC | OXi4503 | II | Solid Tumors |
| Pharmacyclics Inc | PCI24781 | II | Solid Tumors |
| Proteolix Inc | PR171 | II | Solid Tumors |
| Epeius Biotechnologies Corp | Reximmune-C with Rexin-G | II | Solid Tumors |
| Epeius Biotechnologies Corp | Rexin-G | II | Solid Tumors |
| Threshold Pharmaceuticals Inc | TH302 with chemotherapy | II | Solid Tumors |
| Exelixis Inc | XL147 with Paclitaxel and Carboplatin | II | Solid Tumors |
| OXiGENE INC | Zybrestat with Radiotherapy | II | Solid Tumors |
Thyroid Cancer
Thyroid cancer is a rare type of cancer. The thyroid makes hormones that regulate the way your body uses energy and that help your body work normally. Four main types of thyroid cancer are papillary, follicular, medullary, and anaplastic thyroid cancer. The four types are based on how the cancer cells look under a microscope. There were 37,340 new cases in 2008 according to the National Cancer Institute.
| Company | Product | Phase | |
| Exelixis Inc | XL184 | II | Thyroid Cancer |
| OXiGENE INC | Zybrestat with Paclitaxel and Carboplatin | II | Thyroid Cancer |
| Amgen Inc | AMG706 | II | Thyroid Cancer |
| Onyx Pharmaceuticals Inc | Nexavar | II | Thyroid Cancer |
| OXiGENE INC | Zybrestat | II | Thyroid Cancer |